DOCSLIB.ORG

NOT ALL ESTROGENS ARE CREATED EQUAL: What You Need to Know

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
NOT ALL ESTROGENS ARE CREATED EQUAL: What You Need to Know NOT ALL ESTROGENS ARE CREATED EQUAL: What You Need to Know Dr Nyjon K Eccles BSc MBBS MRCP PhD & Sergey Dzugan MD PhD Fig 1. The three main estrogens When discussing estrogen it is important to note that “estrogen” is an umbrella term for many different estrogens. The main three are estriol, estrone, and estradiol; all three of these estrogens are produced in the body and have physiological effects. Some of the benefits of estrogens are: • control hot flashes • maintain pelvic health • improve cognitive function and memory • improve mood • restore sleep • maintain thicKness and fullness of sKin and hair • protect against colon cancer • protect against macular degeneration • prevent atherosclerosis, hypertension • improve insulin sensitivity • prevent osteoporosis 1 • prevent osteoarthritis This list may surprise some people especially given how oestrogen has been demonised as “something to be feared”. It also gives glimpse into why tissues may function less well as estrogens decline at menopause, why certain symptoms occur and the liKely gains from restoring levels of estrogen over and above the elimination of symptoms. The aim of this article is to clarify what we Know about oestrogens and the way to optimise their safe use and also to lay to rest some of the misconceptions and misinformation that are prevalent in the public eye. The number of oocytes (eggs) decrease during ageing which causes a decreased production of estrogen and progesterone starting as early as age 30. Peri- menopause is characterized by infrequent ovulation and low progesterone as the number of functional oocytes progressively declines. Ovarian failure leads to menopause. It is important to note that Coronary heart disease, dementia, osteoporosis, hip fracture, stroKe, ParKinsonism, cognitive impairment, depression, anxiety and breast cancer are associated with estrogen deficiency and all are rare before menopause. The first 3 diseases are clearly associated with estrogen deficiency and breast cancer – with progesterone deficiency. Early removal of the ovaries increases risK of heart disease, osteoporosis, and dementia. Estradiol (E2) and progesterone (P4) collaborate in bone re-modelling with resorption by estrogen and formation by progesterone. It is more liKely that oestrogen together with progesterone are responsible for many of the above protective effects that are usually credited to estrogens alone (1-7). Not all of the 3 main estrogens (see Fig 1) have the same potency. Estradiol (E2) is the predominant estrogen produced in pre-menopausal women while estrone (E1) is the primary estrogen produced after menopause. In the body, estradiol is reversibly oxidized to estrone and both estradiol and estrone can be converted to estriol. The potency of E2 is 12 times that of E1 and 80 times that of E3 (8). In the literature, there is scant information regarding serum estriol values in non- pregnant, premenopausal women. In conventional medical practice, it is believed that estriol plays no significant role in non-pregnant women compared to other estrogens. Dr. Jonathan Wright’s study showed that serum estriol was always significantly higher than the sum of estrone and estradiol and less fluctuating (9). He concluded that estriol is probably a significant estrogen component. Reference values are available for serum estrone and estradiol, but serum estriol levels are listed in reference booKs only for pregnant women. Research on estriol to date had been focused on concentrations in pregnant women. Prior to the 1970s, the technology was not sophisticated enough to accurately analyze estriol in non-pregnant patients and by the time estriol could be analyzed accurately, researchers had already conclusively demonstrated that estriol was a much weaker hormone than estradiol and estrone; therefore, it was believed to be of no known importance. Dr. Wright developed a solid-phase competitive-binding radio-immunoassay (RIA) procedure for estriol. 2 The data showed that the estriol in every case was at least three times as great as the concentration of estradiol and estrone combined. The average Estrogen quotient (EQ = Estriol level/ estradiol + estrone levels) for the population was 8.9. With estriol circulating at nearly 10 times the concentration of estrone and estradiol. It did appear from this data that there must be some unKnown significant biological activity for this “weaker” hormone (9). Furthermore, estriol has been used for decades without reported safety concerns and is a component of medications approved for use worldwide. The FDa has acKnowledged that it is unaware of any adverse events associated with the use of compounded medications containing estriol (10. Studies show that when estriol is given together with estradiol, the estradiol-specific stimulation to cells is decreased (11). Experimental studies also suggest that estriol has a protective effect against radiation-induced cancer of the breast (12). ESTROGEN RECEPTORS Differences in effect of the 3 main estrogens are evident at the receptor level highlighting the liKelihood that not all the estrogens will have the same effects at a cellular level. Estrogen effects are mediated through 2 different estrogen receptors: estrogen receptor-alpha (ER-α) and estrogen receptor-beta (ER-β) (13-18). Estrogen receptor-α promotes breast cell proliferation, while ER-β inhibits proliferation and prevents breast cancer development via G2 cell cycle arrest (13, 19-24). Because of its differing effects on ER alpha and ER beta, we would expect that estriol would be less liKely to induce proliferative [potential cancerous growth] changes in breast tissue and to be associated with a reduced risK of breast cancer (10). Estradiol equally activates ER-α and ER-β, while estrone selectively activates ER-α at a ratio of 5:1 (25,26). In contrast, estriol selectively binds ER-β at a ratio of 3:1(25,26). This unique property of estriol, in contrast to the selective ER-α binding by other estrogens (14, 25-28) imparts to estriol a potential for breast cancer prevention (29- 33) while other estrogens would be expected to promote breast cancer (13,19- 22,34). The above is the reason why doctors who prescribe bio-identical estrogen will tend to combine estriol and estradiol (usually 80:20 ratio) and omit estrone. It is worth noting that conjugated equine estrogens (CEE) are potent down- regulators of ER-β receptors (35). Whether this activity is unique to CEE is unclear, but it could potentially increase carcinogenic properties. CEEs also contains at least one particularly potent carcinogenic estrogen, 4-hydroxy- equilenin, which promotes cancer by inducing DNa damage (36-40). acting alone, estriol is a weak estrogen, but when given with estradiol, it functions as an anti-estrogen (41). Estriol and/or tamoxifen, as opposed to other estrogens, prevented the development of breast cancer in rats after the administration of carcinogens (42,43). 3 In a large study of more than 30 000 women the use of estrogen-only HRT increased the risK of breast cancer compared with that in non-users; the addition of a synthetic progestin further increased breast cancer risK while the use of an estriol-containing preparation was not associated with the risK of breast cancer that was seen with other preparations (44). The increased risK of uterine cancer in users of non-bio-identical estrogen is well- established in the scientific literature (45-47). In contrast, a case-controlled study reported that the use of topical lower-potency estriol is not associated with an increased risK of uterine cancer (48). Estriol and progesterone levels dramatically increase during pregnancy (an approximate 15-fold increase in progesterone and a 1000-fold increase in estriol), and postpartum women continue to produce higher levels of estriol than nulliparous women (49). an increased exposure to progesterone and estriol during and after pregnancy confers a significant long-term reduction in the risK for breast cancer (50, 51-53, 49, 54-58). Urinary estriol levels in postmenopausal women show an inverse correlation with the risK for breast cancer in many studies (59, 60-65). We conclude from all the evidence taken together, that not all estrogens are created equal and that estriol may play a greater role than is currently thought particularly as a more protective estrogen and as a regulator of its more potent sisters (estradiol and estrone). Furthermore, when combined with progesterone rather than with synthetic progestins, the risKs associated with conventional HRT seem to be minimized or even negated. The role and actions of different progesterone and progestins are summarized in a companion article to this one “Not All Progesterones are Created Equal” (https://thenaturaldoctor.org/wp- content/uploads/2019/07/PROGESTERONE-AND-BREAST-CANCER_compressed.pdf). as stated earlier the FDa has not received a single report of an adverse event in more than 40 years of estriol use. The castigation of estriol in recent years did not seem to be because is at least as safe and effective as current estrogens on the marKet, but in response to what was considered unsupported claims that estriol was safer than current forms of estrogen replacement and because there is no standardized dose. as stated above estriol has unique physiologic properties associated with a reduction in the risK of breast cancer, and combining estriol with estradiol in hormone replacement preparations would be expected to decrease the risK for breast cancer; and even moreso when combined with progesterone and not progestins. REFERENCES 1. Seifert-Klauss V, Prior JC. Progesterone and bone: actions promoting bone health in women. J Osteoporos. 2010 Oct 31;2010:845180. 4 2. ParKer WH, Jacoby V, Shoupe D, Rocca W. Effect of bilateral oophorectomy on women's long-term health. Womens Health (Lond Engl). 2009 Sep;5(5):565-76. 3. Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer Ka, Mayer LS, Steffens DC, Breitner JC; Cache County Memory Study Investigators. Hormone replacement therapy and incidence of alzheimer disease in older women: the Cache County Study.
Load more

Recommended publications
  • Alpha-Fetoprotein: the Major High-Affinity Estrogen Binder in Rat
    Proc. Natl. Acad. Sci. USA Vol. 73, No. 5, pp. 1452-1456, May 1976 Biochemistry Alpha-fetoprotein: The major high-affinity estrogen binder in rat uterine cytosols (rat alpha-fetoprotein/estrogen receptors) JOSE URIEL, DANIELLE BOUILLON, CLAUDE AUSSEL, AND MICHELLE DUPIERS Institut de Recherches Scientifiques sur le Cancer, Boite Postale No. 8, 94800 Villejuif, France Communicated by Frangois Jacob, February 3, 1976 ABSTRACT Evidence is presented that alpha-fetoprotein nates in hypotonic solutions, whereas in salt concentrations (AFP), a serum globulin, accounts mainly, if not entirely, for above 0.2 M the 4S complex is by far the major binding enti- the high estrogen-binding properties of uterine cytosols from immature rats. By the use of specific immunoadsorbents to ty. AFP and by competitive assays with unlabeled steroids and The relatively high levels of serum AFP in immature rats pure AFP, it has been demonstrated that in hypotonic cyto- prompted us to explore the contribution of AFP to the estro- sols AFP is present partly as free protein with a sedimenta- gen-binding capacity of uterine homogenates. The results tion coefficient of about 4-5 S and partly in association with obtained with specific anti-AFP immunoadsorbents (12, 13) some intracellular constituent(s) to form an 8S estrogen-bind- provided evidence that at low salt concentrations,'AFP ac-' ing entity. The AFP - 8S transformation results in a loss of antigenic reactivity to antibodies against AFP and a signifi- counts for most of the estrogen-binding capacity associated cant change in binding specificity. This change in binding with the 4-5S macromolecular complex.
    [Show full text]
  • Estriol (Ess-Trye-Ol) Description: Estrogen Hormone Other Names for This Medication: Incurin® Common Dosage Forms: Veterinary: 1 Mg Tablets
    Prescription Label Patient Name: Species: Drug Name & Strength: Directions (amount to give how often & for how long): Prescribing Veterinarian's Name & Contact Information: Refills: [Content to be provided by prescribing veterinarian] Estriol (ess-trye-ol) Description: Estrogen Hormone Other Names for this Medication: Incurin® Common Dosage Forms: Veterinary: 1 mg tablets. Human: None. This information sheet does not contain all available information for this medication. It is to help answer commonly asked questions and help you give the medication safely and effectively to your animal. If you have other questions or need more information about this medication, contact your veterinarian or pharmacist. Key Information Estrogen hormone used in dogs to treat estrogen-responsive urinary incontinence. Most common side effects include lack of appetite, vomiting, greater thirst, and swollen vulva. May give with or without food. If your animal vomits or acts sick after receiving the drug on an empty stomach, try giving the next dose with food or a small treat. If vomiting continues, contact your veterinarian. Pregnant women and those who are breastfeeding should use caution when handling; they should wear disposable gloves when handling the drug. How is this medication useful? The FDA (U.S. Food & Drug Administration) has approved estriol for use in ovariohysterectomized (spayed) female dogs for the control of estrogen-responsive urinary incontinence (urine leaking). The FDA allows veterinarians to prescribe and use products containing this drug in different species or for other conditions in certain situations. You and your veterinarian can discuss why this drug is the most appropriate choice. What should I tell my veterinarian to see if this medication can be safely given? Many things might affect how well this drug will work in your animal.
    [Show full text]
  • Estrogen Pharmacology. I. the Influence of Estradiol and Estriol on Hepatic Disposal of Sulfobromophthalein (BSP) in Man
    Estrogen Pharmacology. I. The Influence of Estradiol and Estriol on Hepatic Disposal of Sulfobromophthalein (BSP) in Man Mark N. Mueller, Attallah Kappas J Clin Invest. 1964;43(10):1905-1914. https://doi.org/10.1172/JCI105064. Research Article Find the latest version: https://jci.me/105064/pdf Journal of Clinical Investigation Vol. 43, No. 10, 1964 Estrogen Pharmacology. I. The Influence of Estradiol and Estriol on Hepatic Disposal of Sulfobromophthalein (BSP) inMan* MARK N. MUELLER t AND ATTALLAH KAPPAS + WITH THE TECHNICAL ASSISTANCE OF EVELYN DAMGAARD (From the Department of Medicine and the Argonne Cancer Research Hospital,§ the University of Chicago, Chicago, Ill.) This report 1 describes the influence of natural biological action of natural estrogens in man, fur- estrogens on liver function, with special reference ther substantiate the role of the liver as a site of to sulfobromophthalein (BSP) excretion, in man. action of these hormones (5), and probably ac- Pharmacological amounts of the hormone estradiol count, in part, for the impairment of BSP dis- consistently induced alterations in BSP disposal posal that characterizes pregnancy (6) and the that were shown, through the techniques of neonatal period (7-10). Wheeler and associates (2, 3), to result from profound depression of the hepatic secretory Methods dye. Chro- transport maximum (Tm) for the Steroid solutions were prepared by dissolving crystal- matographic analysis of plasma BSP components line estradiol and estriol in a solvent vehicle containing revealed increased amounts of BSP conjugates 10% N,NDMA (N,N-dimethylacetamide) 3 in propylene during estrogen as compared with control pe- glycol. Estradiol was soluble in a concentration of 100 riods, implying a hormonal effect on cellular proc- mg per ml; estriol, in a concentration of 20 mg per ml.
    [Show full text]
  • Vaginal Estriol to Overcome Side-Effects of Aromatase Inhibitors in Breast Cancer Patients
    CLIMACTERIC 2011;14:339–344 Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients G. Pfeiler, C. Glatz, R. Ko¨ nigsberg*, T. Geisendorfer{, A. Fink-Retter, E. Kubista**, C. F. Singer and M. Seifert Department of Gynecology and Gynecological Oncology, Medical University of Vienna; *Applied Cancer Research – Institution for Translational Research Vienna (ACR-ITR VIEnna)/CEADDP, Vienna; {Chemical Analytics Seibersdorf Labor GmbH, Seibersdorf; **Department of Special Gynecology, Medical University of Vienna, Austria Key words: BREAST CANCER, VAGINAL ESTRIOL, AROMATASE INHIBITOR, VAGINAL DRYNESS, DYSPAREUNIA ABSTRACT Objective Aromatase inhibitors are essential as endocrine treatment for hormone receptor-positive postmenopausal breast cancer patients. Menopausal symptoms are often aggravated during endocrine treatment. We investigated whether vaginal estriol is a safe therapeutic option to overcome the urogenital side- effects of aromatase inhibitors. Serum hormone levels were used as the surrogate parameter for safety. Methods Fasting serum hormone levels of ten postmenopausal breast cancer patients receiving aromatase inhibitors were prospectively measured by electro-chemiluminescence immunoassays and gas chromatography/ mass spectrometry before and 2 weeks after daily application of 0.5 mg vaginal estriol (Ovestin1 ovula), respectively. Results Two weeks of daily vaginal estriol treatment did not change serum estradiol or estriol levels. However, significant decreases in levels of serum follicle stimulating hormone (p ¼ 0.01) and luteinizing hormone (p ¼ 0.02) were observed. Five out of six breast cancer patients noticed an improvement in vaginal dryness and/or dyspareunia. Conclusions The significant decline in gonadotropin levels, indicating systemic effects, has to be kept in mind when offering vaginal estriol to breast cancer patients receiving an aromatase inhibitor.
    [Show full text]
  • Table E-46. Therapies Used in Trials Comparing Hormone with Placebo Ar Est Study N Rxcat Dose Route Generic Trade M Dose Martin 1971 1 56 Plac Oral
    Table E-46. Therapies used in trials comparing hormone with placebo Ar Est Study N RxCat Dose Route Generic Trade m Dose Martin 1971 1 56 Plac Oral Standar 2 53 EP seq 0.025 mg E + 1 mg P Oral mestranol + norethindrone d 3 56 EP seq 0.05 mg E + 1 mg P Oral mestranol + norethindrone High Campbell 1 68 Plac Oral 1977 2 68 Est 1.25 mg Oral conjugated equine estrogens Premarin High Baumgardner 1 42 Plac Oral 1978 2 42 Est 0.1 mg Oral quinestrol Estrovis Low Standar 3 35 Est 0.2 mg Oral quinestrol Estrovis d 4 37 Est 1.25 mg Oral conjugated estrogen Premarin High E-65 Ar Est Study N RxCat Dose Route Generic Trade m Dose Coope 1981 1 26 Plac Oral UltraLo 2 29 Est 0.3mg Oral piperazine estrone sulphate w Jensen 1983 1 90 Plac Oral estradiol + estriol + 2 41 EP seq 4 mg E + 1 mg P Oral Trisequens Forte High norethisterone acetate Foidart 1991 1 53 Plac VagPes Ortho-Gynest- 2 56 Est 1 mg VagPes estriol Low Depot Eriksen 1992 1 79 Plac VagTab 2 75 Est 0.025 mg VagTab estradiol Vagifem Low Wiklund 1993 11 1 Plac Patch 1 11 Standar 2 Est 0.05 mg Patch estradiol 2 d Derman 1995 1 42 Plac Oral Standar 2 40 EP seq 2 mg E + 1 mg P Oral estradiol + norethindrone acetate Trisequens d Saletu 1995 1 32 Plac Patch Standar 2 32 Est 0.05 mg Patch estradiol Estraderm d Good 1996 1 91 Plac Patch Standar 2 88 Est 0.05 mg Patch estradiol Alora d 3 94 Est 0.10 mg Patch estradiol Alora High Speroff (Study 1) 1 54 Plac Patch 1996 UltraLo 2 54 Est 0.02 mg Patch estradiol FemPatch w E-66 Ar Est Study N RxCat Dose Route Generic Trade m Dose Chung 1996 1 40 Plac Oral Standar
    [Show full text]
  • Repurposing the Estrogen Receptor Modulator Raloxifene to Treat SARS
    www.nature.com/cdd REVIEW ARTICLE OPEN Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 infection ✉ Marcello Allegretti 1 , Maria Candida Cesta 1, Mara Zippoli1, Andrea Beccari1, Carmine Talarico1, Flavio Mantelli1, Enrico M. Bucci 2, Laura Scorzolini3 and Emanuele Nicastri3 © The Author(s) 2021 The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) necessitates strategies to identify prophylactic and therapeutic drug candidates to enter rapid clinical development. This is particularly true, given the uncertainty about the endurance of the immune memory induced by both previous infections or vaccines, and given the fact that the eradication of SARS-CoV-2 might be challenging to reach, given the attack rate of the virus, which would require unusually high protection by a vaccine. Here, we show how raloxifene, a selective estrogen receptor modulator with anti-inflammatory and antiviral properties, emerges as an attractive candidate entering clinical trials to test its efficacy in early-stage treatment COVID-19 patients. Cell Death & Differentiation; https://doi.org/10.1038/s41418-021-00844-6 FACTS (3) If successful, the ongoing clinical study on raloxifene, a well- known SERM, in paucisymptomatic COVID-19 patients could represent a valid opportunity of treatment for controlling (1) Despite the recent advancements in vaccines development, disease progression. it is still essential not to underestimate the risk associated (4) Validation of the running hypothesis would pave the way for with COVID-19 infection, and to advance knowledge on further investigation on ER modulation as therapeutic specific SARS-CoV-2 pharmacological treatments to cure or approach to treat other infectious diseases.
    [Show full text]
  • Confidential Information Which Is the Property of ITF
    ITFE-2026-C10 (BLISSAFE) EudraCT number: 2014-004517-84 Protocol ITFE-2026-C10 A PHASE II PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND MULTI-CENTRE CLINICAL TRIAL TO ASSESS THE SAFETY OF 0.005 % ESTRIOL VAGINAL GEL IN HORMONE RECEPTOR-POSITIVE POSTMENOPAUSAL WOMEN WITH EARLY STAGE BREAST CANCER IN TREATMENT WITH AROMATASE INHIBITOR IN THE ADJUVANT SETTING. “BLISSAFE Study” Sponsor: ITF RESEARCH PHARMA S.L.U Polígono Industrial de Alcobendas C/San Rafael, 3 28108 Alcobendas (Madrid), Spain Phone: +34 91 6572323 Fax: +34 91 6572366 Email: [email protected] Protocol-specific Sponsor contact information can be found in the Administrative Binder. STUDY CHIEF INVESTIGATOR: Dr. Pedro Sánchez Rovira, Complejo Hospitalario de Jaén Sponsor Study Code: ITFE-2026-C10 EudraCT Number: 2014-004517-84 Protocol Approved by ITF RESEARCH PHARMA (ITF): 26-November-2014 CONFIDENTIAL The information and data included in this protocol contain secrets and privileged or confidential information which is the property of ITF. No one is authorized to make this information public without the written permission of ITF. These limitations shall also be applied to all the information considered to be privileged or confidential and provided in the future. This material can be disclosed and used by its equipment and collaborators as necessary for conducting the clinical trial. Protocol version 1.0: 26-November-2014 Página 1 de 61 ITFE-2026-C10 (BLISSAFE) EudraCT number: 2014-004517-84 SUMMARY OF THE STUDY PROTOCOL Study Title: A PHASE II PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED AND MULTI-CENTRE CLINICAL TRIAL TO ASSESS THE SAFETY OF 0.005% ESTRIOL VAGINAL GEL IN HORMONE RECEPTOR-POSITIVE POSTMENOPAUSAL WOMEN WITH EARLY STAGE BREAST CANCER IN TREATMENT WITH AROMATASE INHIBITOR IN THE ADJUVANT SETTING.
    [Show full text]
  • Estriol Face Cream Handout
    is used, most of the time it refers to Estradiol Hormone Health (E2), which is the highest concentration --80%-- during a woman's reproductive years (from & Skin Health puberty to pre-menopause). Estriol (E3) makes Dr. Randolph’s NEW up another 10% and Estrone (E1) makes up the last 10%. Estriol Face Cream Estriol (E3) is considered a "weak" estrogen which can be derived from plant sources. It does What is it? not need to be counterbalanced by progesterone, and does not have a systemic (widespread) effect Dr. Randolph's NEW prescription-only Estriol on the body. This makes estriol an ideal estrogen Face Cream consists of Estriol 0.3% , DMAE for topical use, since research suggests its 3%, and Hyaluronic Acid 0.5% mixed in a cream application remains in the skin, rather than in base. Dr. Randolph, along with Compounding the bloodstream. There is also evidence that Pharmacist Will McGalliard, developed this estriol, (sometimes called the "good estrogen") combination of ingredients to provide a may inhibit some of the unwanted effects of clinically-proven treatment that will boost estradiol by "binding" to estrogen receptors that collagen, reduce wrinkles, improve skin moisture typically promote cell proliferation. and elasticity. Who is it for? How does it work? For women or men who wish to improve the One of the many roles of estrogen in the body is appearance and health of their skin by boosting to increase the synthesis of collagen, which is the the development of underlying collagen skin's underlying support structure. Collagen structure, increasing elasticity and skin moisture, also promotes skin thickness and elasticity.
    [Show full text]
  • Print Your Doctor Discussion Guide
    Doctor Discussion Guide What to Ask What& toTell Talking about painful intercourse due to menopause with your doctor. What matters most when speaking with your doctor is STARTING THE CONVERSATION that you are comfortable communicating your needs. Consider the following approaches: • The Direct Approach: “Since menopause, intercourse has been painful. What can I do?” • The Unwelcome Surprise: “You know, I expected hot flashes and night sweats. I never expected pain during intercourse. What can I do?” • The Show-Me: “There’s something else that’s been bothering me. I’d like you to take a look at this.” Then hand your doctor this guide. Asking the right questions is the quickest way WHAT TO ASK to get the information you need. • Is Premarin Vaginal Cream right for my situation? - What are the possible side effects? - How is it used? - How long would I need to use it? INDICATIONS Premarin (conjugated estrogens) Vaginal Cream is used after menopause to treat menopausal changes in and around the vagina and to treat moderate to severe painful intercourse caused by these changes. Each gram contains 0.625 mg conjugated estrogens, USP. IMPORTANT SAFETY INFORMATION (continued on following page) Using estrogen-alone may increase your chance of getting cancer of the uterus (womb). Report any unusual vaginal bleeding right away while you are using Premarin (conjugated estrogens) Vaginal Cream. Vaginal bleeding after menopause may be a warning sign of cancer of the uterus (womb). Your healthcare provider should check any unusual vaginal bleeding to find out the cause. Do not use estrogens, with or without progestins, to prevent heart disease, heart attacks, strokes or dementia (decline in brain function).
    [Show full text]
  • Drugs for the Treatment of Menopausal Symptoms
    Review Drugs for the treatment of menopausal symptoms † Susan R Davis & Fiona Jane Monash University, Alfred Hospital, Central Clinical School, Women’s Health Program, 1. Introduction Commercial Road, Prahran, Victoria, Australia 2. Which menopausal symptoms Importance of the field: Over the last decade, the management of the meno- merit treatment? pause has attracted extensive public and professional debate and has become 3. Pharmacotherapy for one of the most controversial areas in clinical practice. menopausal symptoms Areas covered in this review: This review provides an overview of the field, 4. New frontiers primarily from a clinical practice perspective. However, as we have incorpo- 5. Expert opinion rated in this ‘big-picture’ snapshot of the field both conventional and comple- mentary approaches to managing the menopause, it is not an exhaustive review of the literature. What the reader will gain: By reviewing menopausal management from the perspective of practicing clinicians, we hope readers will gain insight into decision making processes appropriate for dealing with symptomatic women. Take home message: Although most women do not require pharmacother- apy for menopausal symptoms, many are severely affected by estrogen defi- ciency at and beyond menopause and, for such women, hormone therapy is important if they are to retain an acceptable quality of life. This article consid- ers the drug treatment of the symptomatic postmenopausal woman and the safety issues related to these medications. Keywords: estrogen, HRT, menopause, progestogen Expert Opin. Pharmacother. (2010) 11(8):1329-1341 For personal use only. 1. Introduction Menopause is not only associated with symptoms that range from bothersome through to extremely distressing, it is also accompanied by hormonal changes that impact adversely on several non-reproductive systems.
    [Show full text]
  • HRT Formulary and Treatment Guidance
    Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care Alliance HRT formulary and treatment guidance [APC ClinDoc 010) For the latest information on interactions and adverse effects, always consult the latest version of the Summary of Product Characteristics (SPC), which can be found at: http://www.medicines.org.uk/ Approval and Authorisation Approved by Job Title Date Area Prescribing APC Chair January 2016 Committee Change History Version Date Author Reason v.1.0 09/2018 - Updated APC Category This prescribing guideline remains open to review considering any new evidence This guideline should only be viewed online and will no longer be valid if printed off or saved locally Author - Date of production: January 2016 Job Title - Review Date May 2019 Protocol Lead - Version v 1.0 Berkshire West CCGs HRT formulary and treatment guidance Contents ñ Formulary Oral or transdermal HRT—ofer choice but avoid oral if ñ Diagnosing menopause and need for treatment ñ VTE risks or personal /frst degree relatve with history ñ Initatng and managing HRT Patent assessment ñ Poor symptom control with oral Choice of HRT route ñ Bowel disorder /absorpton problems /gastric banding Types of treatment regimes ñ Lactose intolerance Topical oestrogen ñ History of migraines Dose, duraton and weaning of HRT ñ Tibolone Stroke risks e.g. BMI>30/smoker/sedentary ñ Contraindicatons, cautons and risks of HRT ñ History of or
    [Show full text]
  • Label Extension of HERS, HERS II
    Depo®-Estradiol Estradiol cypionate injection, USP WARNINGS: ESTROGENS INCREASE THE RISK OF ENDOMETRIAL CANCER. Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding. There is currently no evidence that the use of “natural” estrogens result in a different endometrial risk profile than “synthetic” estrogens at equivalent estrogen doses. (See WARNINGS, malignant neoplasms, Endometrial cancer.) CARDIOVASCULAR AND OTHER RISKS Estrogens with and without progestins should not be used for the prevention of cardiovascular disease. (See WARNINGS, Cardiovascular disorders.) The Women’s Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) during 5 years of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo. (see CLINICAL PHARMACOLOGY, Clinical Studies.) The Women’s Health Initiative Memory Study (WHIMS), a substudy of WHI, reported increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with oral conjugated estrogens plus medroxyprogesterone acetate relative to placebo. It is unknown whether this finding applies to younger postmenopausal women or to women taking estrogen alone therapy. (See CLINICAL PHARMACOLOGY, Clinical Studies.) Other doses of conjugated estrogens with medroxyprogesterone acetate, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar.
    [Show full text]